Geode Capital Management LLC Grows Stock Holdings in NewAmsterdam Pharma (NASDAQ:NAMS)

Geode Capital Management LLC increased its stake in NewAmsterdam Pharma (NASDAQ:NAMS) by 1.6% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 86,322 shares of the company’s stock after buying an additional 1,399 shares during the period. Geode Capital Management LLC’s holdings in NewAmsterdam Pharma were worth $1,433,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Sei Investments Co. boosted its holdings in NewAmsterdam Pharma by 49.1% in the second quarter. Sei Investments Co. now owns 24,561 shares of the company’s stock worth $472,000 after acquiring an additional 8,087 shares in the last quarter. Affinity Asset Advisors LLC boosted its stake in NewAmsterdam Pharma by 47.9% in the 2nd quarter. Affinity Asset Advisors LLC now owns 423,155 shares of the company’s stock worth $8,129,000 after purchasing an additional 136,955 shares in the last quarter. Decheng Capital LLC bought a new position in NewAmsterdam Pharma in the 2nd quarter worth about $7,684,000. Deerfield Management Company L.P. Series C grew its position in NewAmsterdam Pharma by 30.3% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 869,250 shares of the company’s stock valued at $16,698,000 after purchasing an additional 202,250 shares during the last quarter. Finally, Millennium Management LLC increased its stake in NewAmsterdam Pharma by 23.0% during the 2nd quarter. Millennium Management LLC now owns 1,165,429 shares of the company’s stock valued at $22,388,000 after purchasing an additional 217,902 shares in the last quarter. Institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Stock Down 1.9 %

NASDAQ:NAMS opened at $25.55 on Friday. The company has a 50 day simple moving average of $23.27 and a two-hundred day simple moving average of $19.64. NewAmsterdam Pharma has a 12 month low of $12.04 and a 12 month high of $27.29.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Piper Sandler reiterated an “overweight” rating and set a $37.00 price target on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Scotiabank upped their price objective on NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a “sector outperform” rating in a research report on Wednesday, December 11th. Needham & Company LLC reissued a “buy” rating and issued a $36.00 target price on shares of NewAmsterdam Pharma in a report on Thursday, December 5th. Finally, HC Wainwright initiated coverage on NewAmsterdam Pharma in a research note on Monday, December 30th. They issued a “buy” rating and a $48.00 price target for the company. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $38.17.

Insider Buying and Selling

In other NewAmsterdam Pharma news, major shareholder Nap B.V. Forgrowth sold 8,530 shares of the stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $25.02, for a total value of $213,420.60. Following the transaction, the insider now directly owns 11,812,033 shares in the company, valued at approximately $295,537,065.66. This trade represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 446,730 shares of company stock valued at $11,438,695 over the last 90 days. Company insiders own 19.50% of the company’s stock.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.